By abhat@reaganud… on
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?term=roivant&Search=Apply&recrs=a&recrs=f&recrs=d&recrs=c&recrs=k&age_v=&gndr=&type=&rslt=
COVID-19 Information

Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19

  • Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients
  • Emerging clinical evidence in COVID-19 patients suggests that GM-CSF contributes to immunopathology caused by SARS CoV-2 in patients with or at risk of developing ARDS
  • ARDS is a serious complication of COVID-19 which necessitates hospitalization and mechanical ventilation or other life support measures
  • A Phase 1 study of gimsilumab conducted by Roivant completed dosing last month following extensive non-clinical research; gimsilumab treatment has been associated with a favorable safety and tolerability profile to date
Stage
Phase 1
Company Type
Late Onset Intervention